Company Intelligence Profile
Morepen Laboratories Limited
Morepen Laboratories is a 40+ year old pharmaceutical manufacturer headquartered/manufacturing out of Baddi, Himachal Pradesh (10 plants).
Last updated 6 September 2026
Morepen Laboratories Limited, established in 1984, is a pharmaceutical manufacturer based in Baddi, Himachal Pradesh, operating 10 plants. It specializes in global generics, home diagnostics, and OTC healthcare products. The company achieved ₹1,681 crore in revenue and ₹66 crore in profit for FY26, with the Q1 FY27 revenue reaching ₹541 crore.
AI-generated summary from public filings and may contain errors. Verify against the detailed sections below.
See what AICA knows about Morepen Laboratories
Deeper analysis, financial signals and peer comparisons.
Company Identity
| Registered name | Morepen Laboratories Limited |
|---|---|
| CIN | L24231HP1984PLC006028 |
| PAN | AABCM1083B |
| Status |
|
| Listing | Yes — NSE: MOREPENLAB, BSE: 500288 |
| Incorporated | 01 December 1984 |
| ROC | RoC Himachal Pradesh |
| Sector (NIC) |
|
| Registered address |
|
| Authorized capital | ₹250 crore |
| Paid-up capital | ₹109.6 crore (~₹109.58 Cr) |
Business Overview
- Morepen Laboratories is a 40+ year old pharmaceutical manufacturer headquartered/manufacturing out of Baddi, Himachal Pradesh (10 plants)
- Business segments: (1) Global Generics — APIs including montelukast (~45MT/yr capacity) and loratadine (90%+ US market share for the molecule)
- (2) Home Diagnostics — blood glucose monitors, BP monitors, serving 4M+ users
- (3) Dr. Morepen — 400+ OTC healthcare/consumer products including legacy brand Burnol
- (4) Finished formulations across generic therapeutic categories
- Exports to 80+ countries; holds USFDA, WHO-GMP, EU-GMP certifications
- Recently secured an ₹825 crore CDMO mandate and posted highest-ever quarterly revenue in Q1 FY27
Directors
| Name | DIN | Role | Appointed |
|---|---|---|---|
| Sushil Suri | 00012028 | Managing Director | - |
| Sanjay Suri | 00041590 | Whole-time Director | - |
| Praveen Kumar Dutt | 06712574 | Director | - |
| Ranjit Khattar | 00726997 | Director | - |
| Sharad Jain | 06423452 | Director | - |
Financials
- FY26 (year ended March 2026, per Screener.in, standalone/consolidated basis not explicitly labeled — treat as consolidated per Screener convention): Revenue ₹1,681 Cr
- EBITDA ₹112 Cr
- PAT ₹66 Cr
- Net Worth ₹1,243 Cr (Equity Capital ₹110 Cr + Reserves ₹1,133 Cr)
- Borrowings ₹205 Cr. Q1 FY27 (June 2026): Revenue ₹541 Cr, EBITDA ₹80 Cr, PAT ₹54 Cr, EPS ₹0.99
- Cross-check via Tofler (FY 2024-25/March 2025 data): Total Revenue ₹1,500-1,750 Cr band, Net Worth ₹1,077.4 Cr, Total Assets ₹1,778.1 Cr, Borrowings ₹79.4 Cr, Debt-to-Equity 0.04 — figures are broadly consistent with revenue growing YoY into FY26, though Tofler's FY25 borrowings figure (₹79.4 Cr) is notably lower than Screener's FY26 figure (₹205 Cr), a real reported increase rather than a conflict
In the News
Morepen Laboratories Bags ₹825 Crore Global Deal, Expands Into High-Growth CDMO Segment
scanx.trade · 2 months ago
Morepen Laboratories files FY26 BRSR report, details sustainability metrics
scanx.trade · 2 months ago
Morepen Laboratories sets Sept 26 for 41st AGM; proposes ₹0.20 dividend
scanx.trade · 2 months ago
Morepen Laboratories Ltd. Key Financial Ratios – Valuation, Profitability & More
Value Research · 2 months ago
Morepen Laboratories Share Price today after yearly high
Univest · 2 months ago
Headlines about Morepen Laboratories Limited reported by third-party publications. Recur Club does not author or endorse this coverage. Last checked 9/6/2026.
Source: Google News aggregated headlines
Charges/Loans
- Kotak Mahindra Bank Limited — ₹99.0 Cr (charge dated Jan 20, 2025)
- Qatar National Bank — ₹50.0 Cr (May 23, 2025)
- Mercedes-Benz Financial Services — ₹4.8 Cr across 4 loans
- Kotak Mahindra Prime Limited — ₹4.0 Cr across 12 loans
- BMW India Financial Services — ₹1.2 Cr
Legal
- Indian Kanoon search surfaced multiple historical cases involving Morepen Laboratories Limited (company as party, not necessarily current/active litigation): Morgan Securities and Credits Pvt. Ltd. vs Morepen Laboratories Ltd. (Delhi HC, 17 Jul 2006 — loan recovery, Rs.5 Cr)
- Morepen Laboratories Limited vs SEBI (Securities Appellate Tribunal, 15 Apr 2021 — regulatory matter)
- Morepen Laboratories Ltd vs Union of India (Supreme Court, 14 Jan 2011 — SLP)
- Morepen Laboratories Ltd vs Phafag AG and Ors (Delhi HC, 28 Feb 2013 — appeal)
- Biocon Limited vs Morepen Laboratories Ltd. (Delhi HC, 22 Feb 2010 — commercial dispute)
- Rahul Srivastava & Anr vs Morepen Laboratories Ltd & Ors (Delhi HC, 15 Jan 2019)
- Euro Containers vs Morepen Laboratories Ltd. (Himachal Pradesh HC, 23 Mar 2006)
- Morepen Laboratories Ltd. vs T.S. Geetha (Kerala State Consumer Disputes Commission, 24 Dec 2011)
Competitors
Frequently Asked Questions
What does Morepen Laboratories Limited do?
What is the CIN of Morepen Laboratories Limited?
Where is Morepen Laboratories Limited registered?
When was Morepen Laboratories Limited incorporated?
Recur Market
Which lenders fit a company like Morepen Laboratories Limited?
Answer a few questions about your business and see which banks and NBFCs match, with indicative rates.
More on Recur Club
Recently added companies
Lenders on Recur Club
Explore on Recur Club
More from Recur Club
Looking for business funding?
Recur Club is India's largest AI-native debt platform - working capital, term loans and structured debt from 150+ lending partners, without diluting equity.